Pharma, AI & Energy Mega Licensing Wave
A surge in landmark licensing deals and strategic alliances — spanning Pfizer's $1B antibody drug conjugate pact, Anthropic's $35B Nvidia-backed cloud agreement, and cross-sector energy and tech partnerships — is creating sharp premium-driven re-ratings across pharma, AI infrastructure, and commodity-linked equities as high-value alliance structures signal accelerating revenue visibility and competitive moat expansion. Investors are repricing growth premiums across NVDA, PFE, GOOGL, CVX, BTC, and USDC as partnership announcements bridge traditional sector boundaries and unlock new institutional capital deployment pathways.
相關資產
| 資產 | 價格 | 24小時漲跌 | 板塊 |
|---|---|---|---|
APPApplovin Corporation | $266.03 | -4.82% | general |
CRVCurve DAO | $0.34 | -3.44% | — |
HOODRobinhood Markets, Inc. Class A Common Stock | $98.23 | -3.97% | general |
GLNDGreenland Energy Company | — | +0.00% | — |
ABTAbbott Laboratories | $104.77 | +0.03% | healthcare |
AEISAdvanced Energy Industries, Inc. | $352.5 | +0.79% | energy stocks |
FOGOFogo | $0 | -5.29% | — |
CNQCanadian Natural Resources Limited | $53.77 | +3.48% | general |
AU10YAustralia 10 Year Yield | $5.26 | +1.15% | us indices |
USDBRLUS Dollar / Brazilian Real | $5.11 | -0.39% | forex exotics |
AMATApplied Materials, Inc. | $410.69 | -3.08% | semis |
LITELumentum Holdings Inc. | $819.75 | -4.73% | general |
DVNDevon Energy Corporation | $50.67 | +2.82% | energy stocks |
HYPEHyperliquid | $78.74 | -3.16% | — |
LMTLockheed Martin Corporation | $551.99 | +3.40% | industrial |
ZSZscaler, Inc. | $207.51 | -5.91% | tech |
CMGChipotle Mexican Grill, Inc. | $29.84 | -2.29% | semis |
CLSCelestica Inc. | $303.55 | -3.56% | general |
CRDOCredo Technology Group Holding Ltd | $169.72 | -4.88% | general |
BNBBinance Coin | $719.8 | -1.23% | — |
最新市場快訊
博通擬向Anthropic提供高達420億美元貸款以租賃晶片 — AVGO差價合約槓桿情境與跨市場影響
據報導,博通(Broadcom)擬向Anthropic提供高達420億美元的貸款,用於租賃晶片,鎖定龐大的未來營收。AVGO目前交易價為353.42美元,359.11美元為即時的看漲觸發價;槓桿差價合約交易者面臨50倍槓桿下緊縮的清算區間,應在市場確認後再增加部位規模。
InnoCare–Eli Lilly $3.35B Deal Claim: What the Evidence Actually Shows
The reported InnoCare–Eli Lilly $3.35B deal is unverified; confirmed evidence points to a separate InnoCare–Zenas BioPharma transaction and a minor asset return to Lilly — do not trade LLY on this headline without corroboration.
相關板塊
準備好交易了嗎?
在 CoinUnited.io 以最高 2,000 倍槓桿交易與「Pharma, AI & Energy Mega Licensing Wave」主題相關的資產。
在 CoinUnited.io 開始交易 →